Goldman Sachs’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Goldman Sachs’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,367	Closed	-$316K	–	7373
2016 Q1	$316K	Buy	+4,367	New	+$324K	﹤0.01%	5228

Other funds holding ZBIO

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Goldman Sachs's ZBIO Position: Q2 2016 in Review

Goldman Sachs sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q2 2016, closing a stake of 4,367 shares — an estimated $316K sold.

Goldman Sachs first reported a position in ZBIO in Q1 2016 and held it in 1 quarter. The position peaked at $316K in Q1 2016. 7 funds tracked by Wall St. Rank hold ZBIO as of Q2 2016.

Goldman Sachs reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q2 2016 after selling out during the quarter.
Goldman Sachs sold 4,367 ProShares UltraPro Short NASDAQ Biotechnology shares in Q2 2016, an estimated $316K.
Goldman Sachs first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q1 2016 and held it in 1 quarter.
Goldman Sachs's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $316K in Q1 2016.
7 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q2 2016.

Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.